Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Constant Rate Shuttle Walking and Stair Stepping Tests to Assess Exertional Dyspnea in COPD: Responsiveness to Pulmonary Rehabilitation and Minimal Clinically Important Difference
This is a multi-site collaborative study that will be done in the context of three Quebec hospitals' outpatient pulmonary rehabilitation programs: Montreal Chest Institute; University of Laval, and Hopital Sacre-Coeur Montreal. The objectives are two-fold. First, to determine the Minimal Clinical Important Difference in intensity ratings of perceived breathlessness for each of the 3-min constant rate shuttle walking (3-MWT) and stair stepping (3-MST) protocols in patients with chronic obstructive pulmonary disease (COPD). Second, to test the hypothesis that both the 3-MWT and 3-MST protocols are able to detect statistically significant and clinically-meaningful improvements in exertional breathlessness following an 7-12 week outpatient rehabilitative exercise training program in COPD.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | August 2018 |
Est. primary completion date | April 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Male or Female - Ambulatory - Moderate-to-very severe COPD (GOLD Stage 2-4) Exclusion Criteria: - Respiratory exacerbation in the previous 6 weeks - Change in medication dosage/frequency in the previous 6 weeks - Clinical evidence of asthma - Cardiovascular and/or neuromuscular diseases that are unstable and/or that may contribute to exercise limitation - Any other contraindications to exercise training/testing |
Country | Name | City | State |
---|---|---|---|
Canada | McConnell Centre for Innovative Medicine, Research Institute of the McGill University Health Centre | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
McGill University | Laval University, Mount Sinai Hospital, Montreal |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change (post- minus pre- pulmonary rehab) in spirometry (FEV1, FVC, and FEV1/FVC) | expressed in L and as % predicted | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) in lung volumes (TLC, FRC, RV) | expressed in L and as % predicted | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) in airways resistance (Raw, sRaw) | expressed in L and as % predicted | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) CCQ | questionnaire | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) CRQ | questionnaire | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) IPAQ | questionnaire | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) BDI/TDI | questionnaire | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) CAT | questionnaire | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) in Exercise Endurance Time (EET) to constant power output cycling exercise performed at 75% of the peak incremental cycling power output achieved prior to start of pulmonary rehab | EET, in minutes and sec | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) in peak VO2 to constant power output cycling exercise performed at 75% of the peak incremental cycling power output achieved prior to start of pulmonary rehab | in ml/kg/min and as %predicted | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) in peak Ventilation to constant power output cycling exercise performed at 75% of the peak incremental cycling power output achieved prior to start of pulmonary rehab | in L/min, as %predicted and as % of MVV (=FEV1x35) | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) in the 6-minute walk distance | in m | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) in body composition assessed by dual-energy X-ray absorptiometry | Lean body mass (g) | Baseline and 7 weeks | |
Other | Change (post- minus pre- pulmonary rehab) in isometric quadriceps peak torque | % predicted | Baseline and 7 weeks | |
Primary | Minimal clinically important difference (MCID) with regards to the change in breathlessness intensity ratings at the end of each of the 3-MST and 3-MWT. | Baseline and 7 weeks | ||
Secondary | Change (post- minus pre- pulmonary rehab) in dyspnea intensity ratings on the Borg 0-10 ratio category scale | Borg 0-10 category ratio scale | Baseline and 7 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|